A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.
Dongjian ChenYu ZhuZhi ChengSongfu JiangHaiyan HeWan-Ting QiangFang XiangXuedong SunJuan DuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
HDS269B is effective and safe, especially for patients with ECOG scores 0 to 2. Early CAR T-cell intervention may improve prognosis in patients with RRMM.